Skip to content

Milestones

  • Company formation

  • May 2017
  • Convertible note financing

  • August 2019
  • Australian regulatory approval for Phase 1 study in patients with retinal detachment

  • October 2019
  • ONL1204 patent issued in US

  • March 2020
  • Phase 1 study in patients with retinal detachment; Safety Review Committee clears Cohort 2 (50 µg)

  • December 2020
  • Australian regulatory approval for Phase 1b study in patients with GA secondary to AMD

  • May 2021
  • First patient screened in GA Phase 1 clinical trial

  • October 2021
  • Series B financing – Tranche 2 closes

  • February 2011
  • Series A financing

  • September 2018
  • Convertible note financing

  • October 2019
  • First patient dosed, first in human clinical trial in retinal detachment

  • December 2019
  • Phase 1 study in patients with retinal detachment; Safety Review Committee clears Cohort 1 (25 µg)

  • November 2020
  • Series B financing – Tranche 1 closes

  • January 2021
  • Phase 1 study in patients with retinal detachment; Safety Review Committee clears Cohort 3 (100 µg)

  • July 2021
  • First patient dosed in GA Phase 1 clinical trial (dose escalation phase)

  • January 2022